First of Its Kind AI-Guided Test Distinguishes Prostate Cancer from Benign Prostatic Hyperplasia
|
By LabMedica International staff writers Posted on 30 Jun 2023 |
|
A pioneering diagnostic panel, developed using artificial intelligence (AI), offers a non-invasive, non-PSA-based screening test for prostate cancer. The test can differentiate prostate cancer from benign prostatic hyperplasia (BPH) cases and also rule out aggressive prostate cancers, preventing unnecessary biopsies in men with BPH who typically present with elevated prostate-specific antigen (PSA).
BPGbio, Inc. (Framingham, MA, USA) has developed a prostate cancer screening test using proprietary technology, which employs AI to analyze tissue and blood samples and distinguish between healthy and cancerous samples. BPGbio's technology is based on its Interrogative Biology platform that combines AI with a comprehensive biobank of patient samples to identify potential biomarkers. The company then uses the unique biomarkers discovered to create diagnostics and screening tests, such as for prostate cancer. This biobank has been built over 12 years through collaborations with hospitals and medical schools and includes blood samples, tissues, and demographic data.
The biomarkers are detected de novo using data generated through internal analysis and the company's analytics tools. Depending on their interconnections in the data knowledge graphs created by BPGbio, these markers are further evaluated for their potential diagnostic capability. They are also examined to ascertain whether they are affected by demographics, comorbidities, or concurrent medications. The markers being examined are diverse, encompassing genetic mutations, gene expression, protein measurements, structural lipids, signaling lipids, metabolites, and protein post-translational modifications like phosphorylation or acetylation.
BPGbio developed the mass spectrometry-based blood test after analyzing tissue and samples collected quarterly for over 20 years from soldiers to discover a novel biomarker, filamin-A. This biomarker can differentiate between BPH and aggressive prostate cancer in patients with elevated PSA levels. Filamin-A interacts directly with the androgen receptor, linked to prostate cancer proliferation and progression, and is involved in calcium signaling, which activates prostate cancer progression pathways. BPGbio has completed late-stage clinical trials for the prostate cancer test and is presently determining how to best commercialize it in the US and internationally, particularly in Latin America and India.
Additionally, BPGbio is leveraging its technology to develop a similar breast cancer test, along the lines of its successful prostate cancer test. The new AI-developed panel aims to identify women diagnosed with ER+ breast cancer who do not respond to hormone therapy, enabling them to avail more effective treatment options. Through its research, the company has identified 34 genes that could provide deeper insight into the cancer's metastatic potential than pathology. The awareness of these genes can encourage clinicians to treat patients more aggressively for whom hormone therapy is likely to be ineffective. While the prostate cancer test is close to being commercialized, the next-generation sequencing-based breast cancer panel is still in the prospective validation stage. The commercial breast cancer panel will likely include all 34 genes and other genes to normalize the signature.
Using similar methodologies for the development of its prostate and breast cancer tests, BPGbio is also working on diagnostic tests for pancreatic cancer and Parkinson's disease. The pancreatic cancer test will be blood-based, while the Parkinson's test will require blood and urine samples. The Parkinson's test has been validated in a CLIA-certified laboratory and is ready to be launched as a laboratory-developed test. In contrast, the pancreatic cancer test is in analytical development as BPGbio is validating its biomarkers.
Related Links:
BPGbio, Inc.
Latest Molecular Diagnostics News
- Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
- Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
- Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
- Urine Test Diagnoses Early-Stage Prostate Cancer
- New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
- Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
- Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy
- Simple Blood Test Better Predicts Heart Disease Risk
- New Blood Test Detects 12 Common Cancers Before Symptoms Appear
- Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
- First-of-its-Kind Blood Test Detects Trauma-Related Diseases
- Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential
- Cheap Cell-Free DNA Based Test Accurately Predicts Preterm Birth
- RNA Blood Test Detects Cancers and Resistance to Treatment
- IL-6 Outperforms Traditional Tests for Early Sepsis Detection
- Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
